IceCure Medical (NASDAQ:ICCM) Issues Earnings Results, Beats Expectations By $3.15 EPS

IceCure Medical (NASDAQ:ICCM) posted its quarterly earnings results on Wednesday. The company reported $1.63 earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.52) by $3.15, reports. The firm had revenue of $0.91 million during the quarter, compared to analyst estimates of $1.45 million. IceCure Medical had a negative net margin of 441.60% and a negative return on equity of 211.73%.

Here are the key takeaways from IceCure Medical’s conference call:

• First-half revenue rose approximately 45% year over year to $1.8 million, driven by higher ProSense system sales and disposable probe utilization. Gross margin improved to 30% from 28%, although foreign-exchange movements limited the benefit.
• The active U.S. commercial install base grew approximately 70% following FDA clearance for early-stage, low-risk breast cancer, reaching more than 30 sites. Management said system purchases increased 20%–25% year over year, with fewer placements as a percentage of activity.
• The FDA-approved ChoICE post-market study is progressing, with two sites fully approved and more than 10 additional sites in process; the company expects first-patient enrollment within three to four weeks and remains confident of enrolling 80 patients by March 2027.
• IceCure ended the first half with approximately $12 million in cash after raising about $8.5 million in gross proceeds during the second quarter, providing funding for commercial, clinical, regulatory, and reimbursement initiatives. However, first-half R&D and sales and marketing expenses increased, and the net loss widened to ILS 8.8 million from ILS 7 million.
• Management said it is advancing its planned CPT Category I reimbursement submission but cannot confirm its status under AMA confidentiality rules; breast-cancer cryoablation is reportedly listed on an upcoming AMA meeting agenda. Japan commercialization efforts are also continuing, though the regulatory process remains lengthy.

IceCure Medical Stock Down 7.7%

ICCM traded down $0.27 during trading on Wednesday, hitting $3.24. The company’s stock had a trading volume of 85,233 shares, compared to its average volume of 1,360,804. The firm’s 50 day moving average price is $4.03 and its two-hundred day moving average price is $10.06. IceCure Medical has a 12 month low of $2.12 and a 12 month high of $42.00. The stock has a market capitalization of $11.11 million, a price-to-earnings ratio of -0.45 and a beta of 0.47.

Analysts Set New Price Targets

Several brokerages recently commented on ICCM. Maxim Group decreased their price target on IceCure Medical from $90.00 to $30.00 and set a “buy” rating on the stock in a research note on Thursday, May 14th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of IceCure Medical in a report on Friday, July 17th. Alliance Global Partners assumed coverage on shares of IceCure Medical in a research report on Monday, May 4th. They set a “buy” rating for the company. Finally, Wall Street Zen raised shares of IceCure Medical to a “sell” rating in a report on Sunday, July 12th. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $62.70.

Institutional Trading of IceCure Medical

An institutional investor recently bought a new stake in IceCure Medical stock. Virtu Financial LLC acquired a new position in shares of IceCure Medical Ltd. (NASDAQ:ICCM) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 64,524 shares of the company’s stock, valued at approximately $39,000. Virtu Financial LLC owned about 0.09% of IceCure Medical as of its most recent SEC filing. 0.62% of the stock is currently owned by institutional investors.

IceCure Medical Company Profile

IceCure Medical Ltd. (NASDAQ: ICCM) is a clinical-stage medical device company specializing in the development and commercialization of proprietary cryoablation systems for the treatment of tumors and other pathological tissues. The company’s core technology employs a unique liquid-nitrogen-based platform to deliver rapid cooling through fine-gauge cryoprobes, enabling precise and minimally invasive tissue ablation under imaging guidance. IceCure’s lead product, ProSense, is designed to offer a single-probe approach that can be deployed in an outpatient setting, reducing procedure time and patient recovery periods.

Originally founded in Israel, IceCure Medical obtained its first CE mark for the treatment of benign breast tumors and fibroadenomas in 2017.